VELMETIA XR 50/500 sitagliptin (as phosphate monohydrate) 50 mg and metformin hydrochloride 500 mg modified release tablet bottle

Country: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

metformin hydrochloride, Quantity: 500 mg; sitagliptin phosphate monohydrate, Quantity: 64.25 mg (Equivalent: sitagliptin, Qty 50 mg)

Disponibbli minn:

Merck Sharp & Dohme (Australia) Pty Ltd

INN (Isem Internazzjonali):

Metformin hydrochloride,sitagliptin phosphate monohydrate

Għamla farmaċewtika:

Tablet, modified release

Kompożizzjoni:

Excipient Ingredients: hypromellose; propyl gallate; kaolin; povidone; colloidal anhydrous silica; macrogol 3350; microcrystalline cellulose; sodium stearylfumarate; Carnauba Wax; titanium dioxide; hyprolose; indigo carmine aluminium lake

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

14 tablets - starter pack, 56 tablets

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

VELMETIA XR (sitagliptin phosphate monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see Sections 5.1 PHARMACODYNAMIC PROPERTIES, Clinical trials and 4.2 DOSE AND METHOD OF ADMINISTRATION].

Sommarju tal-prodott:

Visual Identification: Light blue, bi-convex oval, film coated tablet, debossed "78" on one side and plain on the other.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

L-istatus ta 'awtorizzazzjoni:

Licence status A

Data ta 'l-awtorizzazzjoni:

2014-11-19